The effect of APOE ε4 on striatal vesicular monoamine transporter-2 density in Parkinson’s disease
Objective: To evaluate the effect of apolipoprotein E 4 (APOE 4) on striatal vesicular monoamine transporter-2 (VMAT2) density in Parkinson’s disease (PD).To evaluate the effect…Trajectories of Tardive Dyskinesia Impact Scale (TDIS) and Abnormal Involuntary Movement Scale (AIMS) over time with valbenazine treatment
Objective: To assess TDIS and global AIMS measures change trajectories using data from KINECT-4, an open-label 52-week trial assessing valbenazine in TD [1] Background: AIMS…Real-World Treatment Patterns and Outcomes in Patients With Chorea Associated With Huntington Disease Using Tetrabenazine or Deutetrabenazine in Combination with Antipsychotic Drugs
Objective: To describe treatment patterns with vesicular monoamine transporter 2 inhibitors (VMAT2i; tetrabenazine [TBZ], or deutetrabenazine [DTBZ]) in combination with antipsychotic agents (APs) in patients…A secretory vesicle failure in Parkinson’s disease occurs in human platelets
Objective: Since platelets use similar, if not the same, mechanisms to accumulate serotonin (5-HT) as dopaminergic neurons to store DA in their VS; we wonder…The START Study: A Phase 4 Study on the Real-World Utilization of Deutetrabenazine Initiated by a 4-Week Patient Titration Kit
Objective: To assess the real-world utilization of deutetrabenazine (DTBZ) for the treatment of tardive dyskinesia (TD) or chorea associated with Huntington disease (HD) initiated by…Diagnostic value of striatal [18F]-FP-DTBZ PET in Parkinson’s disease
Objective: To detect the difference of dopaminergic integrity between PDs and healthy controls (HC) using [18F]-FP-DTBZ PET in vivo and to obtain the diagnostic value…Long-term Deutetrabenazine Safety on Motor, Psychiatric, and Cognitive Measures in Individuals With Chorea Associated With Huntington Disease
Objective: To evaluate long-term deutetrabenazine safety on motor, psychiatric, and cognitive measures in participants with chorea associated with Huntington disease (HD). Background: Deutetrabenazine, a vesicular…Baseline Characteristics and Treatment Patterns of a Global Huntington Disease Population Stratified by Chorea Severity
Objective: To describe baseline characteristics and treatment patterns in patients with chorea associated with Huntington disease (HD) by severity of chorea. Background: Though multiple treatment…Predictors of Persistence to Deutetrabenazine Among Patients With Tardive Dyskinesia (TD) and Huntington’s Disease (HD)
Objective: To identify real-world predictors of persistence to deutetrabenazine in patients with TD or HD. Background: Deutetrabenazine is FDA-approved to treat TD in adults and…Cumulative Real-World Experience with Deutetrabenazine for Huntington’s Disease Chorea at a Single Center of Excellence in the US
Objective: To summarize clinical experience and outcomes with deutetrabenazine (DTBZ) as a treatment for Huntington’s disease (HD) chorea from the Huntington’s Disease Society of America…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.